Commentary

Twist in the Tail: Escape from HIV Neutralising Antibodies at a Single Site Confers Broad Susceptibility to Others

Adam K Wheatley, Stephen J Kent

An efficacious vaccine for HIV remains elusive. Numerous groups have isolated antibodies from HIV infected individuals that can bind and neutralise antigenically diverse HIV strains, so-called broadly neutralising antibodies (bNAbs) (Wibmer et al., 2015). HIV bNAbs target several conserved regions on the viral envelope (Env; a heterotrimer composed of gp120 and gp41 subunits) including the CD4 binding site, peptidoglycan associated with either the V1/V2 or the V3 loops, and the gp120-gp41 interface or the membrane proximal external region (MPER) of gp41. Possessing broad and potent antiviral activity, bNAbs may have utility in HIV immunotherapy, and are also an attractive template to guide the rational design of vaccines to generate analogous humoral immunity. However, bNAbs arise in only a minority of infected individuals and have been associated with extended periods of viremic infection and more recently, perturbations in the follicular and regulatory CD4 T cell compartment (Moody et al., 2016). Analysis of isolated bNAb lineages reveals genetic and structural features that likely contribute to their scarcity, including very high rates of somatic mutation, restricted germline selection, frequent genetic insertions and deletions, extended CDR-H3 regions and a propensity for poly- or autoreactivity. The complicated immunological contexts that underpin bNAb development are unlikely to be recapitulated by vaccination. Indeed, generating serum antibody responses able to combat neutralisation-resistant viral isolates (so-called tier 2 viruses) has not been consistently demonstrated by immunisation. Clearer insights into what governs neutralisation sensitivity to bNAbs should help speed further development of bNAb-based immunisation strategies and HIV immunotherapy.

In the current issue of EBioMedicine, Bradley et al. (2016) characterise changes in the gp41 MPER that render HIV isolates with neutralisation-resistant phenotypes sensitive to a range of bNAbs. In a pair of South African individuals infected with clade C virus who developed broadly neutralising antibodies, they identified viral isolates with amino acid changes in the MPER at W680 and Y681 that bestowed resistance to MPER-targeting neutralising antibodies. Interestingly, substitutions at these positions conferred increased sensitivity to bNAbs binding the CD4 binding site or V3 loop regions of Env, some distance from the MPER region. Anti-MPER antibodies isolated from these individuals failed to bind the mutated HIV isolates, suggesting that these viral variants arose in the face of immune pressure from the early autologous neutralising responses. A number of previous studies established that MPER modifications modulate neutralisation sensitivity at distal sites ((Back et al., 1993) and others). However, Bradley et al. comprehensively demonstrate increased susceptibility to heterologous clade C sera, CD4-mimetics, bNAbs and interestingly, vaccine-elicited antibodies in macaques. Hence residue substitutions at positions 680 and 681 within MPER appear to elicid conformational shifts in the Env trimer to favour open structures amenable to neutralisation at other sites, including exposure of both the CD4 binding site and the CCR5 co-receptor binding site in V3. The detailed delineation of specific conformational changes await confirmation by structural biology and/or crystallography.

The complex interplay between viral escape and Env conformation observed by Bradley et al. and others gives some pause to reductionist approaches focussing on recapitulating single bNAb specificities by immunisation. Favourable linkage interactions between different bNAb epitopes, shown here for the MPER and the CD4 binding site or V3 loop, suggests vaccines simultaneously targeted to multiple epitopes may be advantageous. While targeting the MPER by vaccination may be difficult due to described self-mimicry and frequent generation of autoantibodies (Haynes et al., 2005; Williams et al., 2015), the results suggest effective MPER responses may complement neutralisation at alternative epitopes by constraining potential pathways of viral escape. This is supported by observations that combinations of two or more HIV bNAbs may drive some synergistic neutralisation activity beyond the simply additive (Back et al., 1993) and others). However, Bradley et al. (2016) demonstrate increased susceptibility to heterologous clade C sera, CD4-mimetics, bNAbs and interestingly, vaccine-elicited antibodies in macaques. Hence residue substitutions at positions 680 and 681 within MPER appear to elicid conformational shifts in the Env trimer to favour open structures amenable to neutralisation at other sites, including exposure of both the CD4 binding site and the CCR5 co-receptor binding site in V3. The detailed delineation of specific conformational changes await confirmation by structural biology and/or crystallography.

http://dx.doi.org/10.1016/j.ebiom.2016.09.019

Please cite this article as: Wheatley, A.K., Kent, S.J., Twist in the Tail: Escape from HIV Neutralising Antibodies at a Single Site Confers Broad Susceptibility to Others, EBioMedicine (2016), http://dx.doi.org/10.1016/j.ebiom.2016.09.019
be required for HIV therapy. From the perspective of vaccine immuno-
gen design, the study by Bradley et al. highlights the importance of
gp41 MPER residues near the viral membrane in maintaining the
stability of the closed native trimer state. However, it is notable that
the exceptionally well-characterised stabilised Env trimer BG505
SOSIP (truncated at residue 664) lacks this MPER region and has been
experimentally confirmed to exist in a closed, neutralisation resistant
state (Sanders et al., 2013). Future studies aimed at accurately defining
the complex determinants of neutralisation sensitivity will be
informative for both preventive HIV vaccine immunogen design and
for the application of combination HIV bNAb therapy in HIV infected
subjects.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgements

We thank Rebecca Lynch for helpful discussions. Supported by
Australian National Health and Medical Research Council awards
1052979 and 1041832 and the Australian Research Council Centre of
Excellence in Convergent Bio-Nano Science and Technology
(CE140100036).

References

Back, N.K., et al., 1993. Mutations in human immunodeficiency virus type 1 gp41 affect
sensitivity to neutralization by gp120 antibodies. J. Virol. 67 (11), 6897–6902.
Bradley, T., et al., 2016. Amino acid changes in the HIV-1 gp41 membrane proximal region
control virus neutralization sensitivity. EBioMedicine http://dx.doi.org/10.1016/j.
ebiom.2016.08.045.
Caskey, M., et al., 2015. Viraemia suppressed in HIV-1-infected humans by broadly neu-
1038/nature14411.
Haynes, B.F., et al., 2005. Cardiolipin polyspecific autoreactivity in two broadly neutraliz-
org/10.1126/science.1111781.
Kong, R., et al., 2015. Improving neutralization potency and breadth by combining broadly
reactive HIV-1 antibodies targeting major neutralization epitopes. J. Virol. 89 (5),
Lynch, R.M., et al., 2015. Virologic effects of broadly neutralizing antibody VRC01
administration during chronic HIV-1 infection. Sci. Transl. Med. 7 (319), 319ra206.
http://dx.doi.org/10.1126/scitranslmed.aad5752.
Sanders, R.W., et al., 2013. A next-generation cleaved, soluble HIV-1 Env trimer, BG505
SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-
neutralizing antibodies. PLoS Pathog. 9 (9), e1003618. http://dx.doi.org/10.1371/
journal.ppat.1003618.
Williams, W.B., et al., 2015. HIV-1 vaccines. Diversion of HIV-1 vaccine-induced immunity
by gp41-microbiota cross-reactive antibodies. Science (New York, N.Y.) 349 (6249),